Navigation Links
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
Date:5/5/2011

rs of use in the United States. Market data indicate that there is an unmet medical need for a longer-acting anesthetic/analgesic for postsurgical pain management. Several Phase 2 and Phase 3 clinical trials have been completed for EXPAREL and demonstrate statistically significant reduction of pain in soft tissue and orthopedic surgery in different surgical models. Clinical data from Phase 3 trial 316 suggests that EXPAREL provides analgesia for up to 72 hours post-surgery, the primary endpoint for the trial. The safety of EXPAREL was evaluated in 10 randomized, double-blind, local administration into the surgical wound clinical studies involving 823 patients; the most common adverse events following EXPAREL administration were nausea, constipation, and vomiting.

Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about EXPAREL's potential, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the timing of, and our ability to obtain regulatory approval of EXPAREL; the timing of our anticipated commercial launch of EXPAREL; the rate and degree of of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our commercialization and marketing capabilities; and other factors discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2010, and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the dat
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
2. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
4. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
5. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
6. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
7. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
8. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
9. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
10. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
11. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)...  This year alone, The Leukemia & Lymphoma Society ... one goal in mind: Discovering lifesaving therapies for blood ... a flagship LLS fundraising campaign and the world,s first ... landmark 25 th anniversary. To date, TNT has ... to discover and deliver breakthrough cancer treatments that are ...
(Date:6/19/2013)... Pharma IQ is pleased to announce the release ... results from an industry survey conducted earlier this year. ... would be an area of active investment in the next ... more clinical trials in the BRIC region. The infographic, created ... Summit explores the latest trends, challenges and opportunities ...
(Date:6/18/2013)... June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... on the development and commercialization of novel bile acid ... pricing of an underwritten public offering of 1,730,000 shares ... of $33.01 per share.  In addition, Intercept has granted ... an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... 4, 2011 Eli Lilly and Company (NYSE: ... studies of molecules that target genetic mutations and disable ... studies evaluated two unique molecules – a JAK2 inhibitor ... the American Association for Cancer Research (AACR) 102nd Annual ...
... announcing that it entered into an agreement with Oman Pharmaceutical ... Neomycin Sulfate Tablets. Under the terms of the agreement, the ... distributed by Breckenridge on an exclusive basis in the United ... and Drug Administration (FDA), and the companies began shipping the ...
Cached Medicine Technology:Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 2Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 3Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer 4
(Date:6/19/2013)... A University of Iowa study reveals significant disparities ... for completing substance abuse treatment programs. Moreover, these ... , "Our findings suggest that for most states ... professor of psychiatry and biostatistics. "There are strong ... able to complete substance abuse treatment programs successfully, ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on ... half take two, Mayo Clinic researchers say. Antibiotics, ... their study found. Twenty percent of patients are ... the findings, published online in the journal ... audio and video of Dr. Jennifer St. Sauver ...
(Date:6/19/2013)... pharmaceutical companies, along with the Japanese government and ... commitment to bolster Japan,s contribution to global health ... Fund), at a press conference held as a ... on African Development (TICAD V). , Representatives from ... of Health, Labour and Welfare, the Ministry of ...
(Date:6/19/2013)... PREFERRED Therapy Providers, Inc. (PREFERRED) has announced an ... a new Medicare Advantage Plan for PREFERRED’s provider network ... Arizona counties. The agreement takes effect in two stages: ... and Maricopa and Pima counties will become effective on ... of WellCare of Arizona has Medicare Advantage plans in ...
(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... don’t go to bed or rise early thanks to a ... , Crafty travelers will have a little extra change ... Scottsdale Paradise Valley hotel’s Book Early and Save Up ... advance notice, guests can enjoy the year-round Scottsdale sunshine in ...
Breaking Medicine News(10 mins):Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
... Until now, the mode of action of nitrogen-containing bisphosphonate ... to prevent skeletal complications in bone metastasis, has been ... access journal Genome Biology have used ,barcoded, ... the cellular response to N-BPs, opening up opportunities for ...
... , , [Vanderbilt has a 24/7 video and audio ... NASHVILLE, Tenn., Sept. 9 The following is being issued by ... care advisor, Professor of Education and Human Development , Turner, an ... the office of presidential candidate Barack Obama as a Robert Wood Johnson ...
... , , A Center for Public Accountability ... pattern of financial abuses at Tarzana Treatment Center , ... submitted an investigative report to the office of Attorney General Jerry ... may have diverted, or allowed the diversion of, up to $22 ...
... , , , ... a leading provider of kidney care services for those diagnosed with ... treatment options based on optimal patient care standards and social circumstances. ... Victor Tlatelpa, 16, is not your everyday student at ...
... Harvard School of Public Health (HSPH) and Brigham and Women,s ... sexually transmitted infection, Trichomonas vaginalis , and ... The study appears online on September 9, 2009, on the ... will appear in a later print edition. "Prostate cancer ...
... , , CAMARILLO, Calif., Sept. ... National Science Foundation (NSF) recently honored Dr. Blake Gillespie, Assistant ... Development (CAREER) award. , , The ... and research in protein-ligand interactions and biomolecular dynamics, is supported ...
Cached Medicine News:Health News:Vanderbilt Experts For Health Care Debate 2Health News:SEIU Local 721 Calls for Attorney General to Investigate Self-Dealing and $22 Million in Extra Costs at Tarzana Treatment Center 2Health News:DaVita's Patient-Centric Modalities Offer Students with Kidney Disease More Choices 2Health News:Link found between common sexual infection and risk of aggressive prostate cancer 2Health News:CI Faculty Member Awarded Nearly $1 Million NSF Grant 2
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Hook design lifts and separates tissue for efficient dissection. Cautery action facilitates immediate control of bleeders....
The Bair Hugger Model 505 provides safe, quiet and effective warming to patients around the world....
... has it's temperature set by means ... pressing a button. A green LED ... a flashing amber LED indicates the ... A red LED and an audible ...
Medicine Products: